初诊外周T细胞淋巴瘤治疗进展

Advances in the treatment of newly diagnosed peripheral T-cell lymphoma

外周T细胞淋巴瘤(peripheral T-cell lymphoma,PTCL)为一组高度异质性的侵袭性非霍奇金淋巴瘤,整体预后差,目前一线治疗以CHOP(环磷酰胺+阿霉素+长春新碱+泼尼松)方案为主,但复发率较高,最近多项研究报道了初诊PTCL的治疗进展,主要涉及新的化疗方案的探索、新药联合治疗的尝试、自体干细胞移植(autologous stem cell transplantation,ASCT)的应用。新的治疗方案为患者带来了希望,新的分子分型下的靶向治疗可能改变目前的治疗策略。本文就初诊PTCL的治疗进展进行综述。

Peripheral T-cell lymphomas(PTCLs)comprise a group of highly heterogeneous,aggressive non-Hodgkin's lymphomas with a poor overall prognosis.Currently,the first-line treatment for PTCL is the cyclophosphamide+doxorubicin+vincristine+prednisone(CHOP)regimen.However,the recurrence rate is still high.Recently,several studies have reported on the progress in first-line treatments for PTCL.These studies mainly involved the exploration of new chemotherapy regimens,trial of new drugs in combination with chemotherapy,trial of new drug combinations,and the application of autologous stem cell transplantation(ASCT).New therapeutic protocols are a source of hope to patients.Targeted therapy according to the new molecular classification may change the current treatment strategy.This article reviews the advancements in the treatment of newly diagnosed peripheral T-cell lymphoma.